Fritextsökning
Innehållstyper
-
Samuel Lagercrantz: ”Geoffrey Hintons farhågor”
”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
Non-destructive testing and assembly control
Assess complete assembly.
-
Meet us at Control 2025
Innovations that drive efficiency.
-
High-performance Slide Scanner for Fluorescence, Brightfield and Polarization
ZEISS Axioscan 7.
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Moderna develops mRNA vaccine against norovirus
A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
Reduced heat transfer to the media with media-separated valves
In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...
-
Lilly recruits top Swedish researcher in Alzheimer´s
One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.
-
Try arivis for free
30-day free trial offers a number of benefits.
-
Digitala produktpass - från regelverk till konkurrensfördel
Inom EU pågår just nu en omfattande omställning mot mer cirkulära och hållbara affärsmodeller. En viktig pusselbit i detta arbete är införandet av digitala prod...
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...